1.
Number of patients and lesions detected by 68Ga PSMA-PET/CT and sites of relapses in comparison with Caucasian cohorts
| Number of patients (%) | Number of lesions (%) | ||||||
| Overall | PSA ≤
1.0 (ng/mL) |
Comparison against | Caucasian cohorts | Overall | PSA ≤
1.0 (ng/mL) |
||
| Abbreviations: PSA= prostate specific antigen.
Note that percentages do not add up to 100% as both local and distant metastases were present in some patients. | |||||||
| 68Ga PSMA PET/CT +ve | 44 (of 55, 80%) | 11 (of 21, 52%) | PSA 0.2–0.5 (ng/mL)32 | PSA 0.2–0.99 (ng/mL)11 | 168 | ||
| 55% (86 of 134) | 58% | ||||||
| Loco-regional | |||||||
| Prostate bed | 10 (22.7%) | 1 (4.8%) | 27 (20.1%) | 10 (6%) | 1 | ||
| Regional nodes | 18 (40.9%) | 4 (19.0%) | 33 (24.6%) | 33 (19.6%) | 4 | ||
| Metastasis | |||||||
| Non-regional nodes | 9 (20.5%) | 3 (14.3%) | 5 (3.7%) | 30 (17.9) | 3 | ||
| Skeletal | 16 (36.4%) | 4 (19.0%) | 18 (13.4%) | 81 (48.2%) | 26 | ||
| Visceral | 5 (11.4%) | 1 (4.8%) | 3 (2.2%) | 14 (8.3%) | 6 | ||